Analyst Andres Y. Maldonado of H.C. Wainwright maintained a Buy rating on CG Oncology, Inc., retaining the price target of $75.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors including the promising advancements in CG Oncology’s clinical program for cretostimogene. The company is progressing towards approval with the ongoing rolling BLA submission, expected to be completed by 2026. The therapy has shown impressive durability and tolerability in treating NMIBC, particularly in patients unresponsive to BCG, with a significant complete response rate at 24 months.
The safety profile of cretostimogene remains strong, with no severe treatment-related adverse events reported. Additionally, the rapid enrollment in the PIVOT-006 trial highlights the medical community’s interest in this treatment. These developments, coupled with upcoming data releases, suggest that cretostimogene is well-positioned to capture a significant share of the NMIBC market, reinforcing the Buy rating.